{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:10:43Z","timestamp":1785417043559,"version":"3.56.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,22]],"date-time":"2013-07-22T00:00:00Z","timestamp":1374451200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Egyptian National Cancer Institute"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.jnci.2013.05.003","type":"journal-article","created":{"date-parts":[[2013,6,17]],"date-time":"2013-06-17T12:02:26Z","timestamp":1371470546000},"page":"143-150","source":"Crossref","is-referenced-by-count":13,"title":["Transarterial chemoembolization for the treatment of hepatocellular carcinoma: A single center experience including 221 patients"],"prefix":"10.1186","volume":"25","author":[{"given":"Ahmed Abdelmabood","family":"Zeeneldin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem Eid","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda Hassan","family":"Tabashy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa Ahmed","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly Hassan","family":"Alieldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"1","key":"10.1016\/j.jnci.2013.05.003_b0005","first-page":"31","article-title":"Hepatocellular carcinoma in the world and the middle east","volume":"2","author":"Poustchi","year":"2010","journal-title":"Middle East J Digest Dis"},{"key":"10.1016\/j.jnci.2013.05.003_b0010","unstructured":"The National Cancer Registry Program of Egypt (NCRPE). Reports and Statistics: Aswan, Damietta & El-Minia. Available at: <http:\/\/www.cancerregistry.gov.eg\/reports.aspx> (accessed on 05.09.12) [online]."},{"key":"10.1016\/j.jnci.2013.05.003_b0015","series-title":"Cancer incidence in four member countries of the middle east cancer consortium (MECC) Compared with US SEER","year":"2006"},{"key":"10.1016\/j.jnci.2013.05.003_b0290","doi-asserted-by":"crossref","unstructured":"Ahmad J, Rabinovitz M. In: Carr I, editor. Etiology and epidemiology of hepatocellular carcinoma in current clinical oncology: hepatocellular cancer: diagnosis and treatment. Totowa, NJ: Humana Press Inc.; 2005. p. 1\u201322. Available at: <http:\/\/www.springerlink.com\/content\/g06m9020731066gt\/fulltext.pdf> [online].","DOI":"10.1007\/978-1-59259-844-1_1"},{"key":"10.1016\/j.jnci.2013.05.003_b0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/s-2007-1007117","article-title":"Epidemiology of primary liver cancer","volume":"19","author":"Bosch","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jnci.2013.05.003_b0030","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S1386-6346(00)00105-4","article-title":"Prevalence and epidemiological features of hepatocellular carcinoma in Egypt-a single center experience","volume":"19","author":"El-Zayadi","year":"2001","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jnci.2013.05.003_b0035","doi-asserted-by":"crossref","first-page":"14757","DOI":"10.1073\/pnas.1008877107","article-title":"Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt","volume":"107","author":"Miller","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jnci.2013.05.003_b0040","series-title":"Egypt demographic and health survey, 2008","author":"El-Zanaty","year":"2009"},{"issue":"3","key":"10.1016\/j.jnci.2013.05.003_b0045","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00535-005-1566-3","article-title":"Updated treatment approach to hepatocellular carcinoma","volume":"40","author":"Llovet","year":"2005","journal-title":"J Gastroenterol"},{"issue":"December 4","key":"10.1016\/j.jnci.2013.05.003_b0050","first-page":"779","article-title":"Sorafenib for the treatment of unresectable hepatocellular carcinoma","volume":"2","author":"Furuse","year":"2008","journal-title":"Biologics"},{"issue":"19","key":"10.1016\/j.jnci.2013.05.003_b0055","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2010.1672","article-title":"Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial","volume":"304","author":"Abou-Alfa","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jnci.2013.05.003_b0060","series-title":"AJCC cancer staging manual","author":"American Joint Committee on Cancer","year":"2002"},{"issue":"February 3","key":"10.1016\/j.jnci.2013.05.003_b0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jnci.2013.05.003_b0070","unstructured":"Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS [online]. Available at: <http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf> (Publish date: August 9, 2006)."},{"key":"10.1016\/j.jnci.2013.05.003_b0075","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2214\/ajr.182.3.1820643","article-title":"Triple-phase MDCT of hepatocellular carcinoma","volume":"182","author":"Lee","year":"2004","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jnci.2013.05.003_b0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1064-9689(03)00048-5","article-title":"MR imaging of hepatocellular carcinoma","volume":"10","author":"Hussain","year":"2002","journal-title":"Magn Reson Imaging Clin N Am"},{"key":"10.1016\/j.jnci.2013.05.003_b0085","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1055\/s-2008-1040608","article-title":"Pathologic characteristics of hepatocellular carcinoma","volume":"6","author":"Nakashima","year":"1986","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jnci.2013.05.003_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3348\/kjr.2003.4.1.1","article-title":"Detection of small hypervascular hepatocellular carcinomas in cirrhotic patients: comparison of superparamagnetic iron oxide-enhanced MR imaging with dual-phase spiral CT","volume":"4","author":"Lee","year":"2003","journal-title":"Korean J Radiol"},{"issue":"5","key":"10.1016\/j.jnci.2013.05.003_b0095","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3348\/kjr.2009.10.5.425","article-title":"The Current Practice of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma","volume":"10","author":"Shin","year":"2009","journal-title":"Korean J Radiol"},{"issue":"33","key":"10.1016\/j.jnci.2013.05.003_b0100","first-page":"5193","article-title":"Hepatocellular carcinoma in Egypt: a single center study over a decade","volume":"11","author":"El-Zayadi","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jnci.2013.05.003_b0105","unstructured":"The Gharbiah Population-based Cancer Registry (GPCR). Cancer in Egypt, Gharbiah. 2007. Available at: <http:\/\/www.emro.who.int\/ncd\/pdf\/cancer_registry_Egypt.pdf> (Accessed 05.09.12) [online]."},{"issue":"9","key":"10.1016\/j.jnci.2013.05.003_b0110","first-page":"831","article-title":"Prognostic Factors for Survival of Patients with Hepatocellular Carcinoma in National Cancer Institute, Cairo University","volume":"7","author":"Noaman","year":"2011","journal-title":"J Am Sci"},{"key":"10.1016\/j.jnci.2013.05.003_b0115","first-page":"339","article-title":"Outcome of inoperable hepatocellular carcinoma patients receiving transarterial chemoembolisation: a real-life retrospective analysis in a Hong Kong regional hospital","volume":"15","author":"Yip","year":"2009","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.jnci.2013.05.003_b0120","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/hep.510270529","article-title":"Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group","volume":"27","author":"Kasahara","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jnci.2013.05.003_b0125","first-page":"1393","article-title":"Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk","volume":"38","author":"Yu","year":"2003","journal-title":"Hepatology"},{"issue":"15","key":"10.1016\/j.jnci.2013.05.003_b0130","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3748\/wjg.15.1843","article-title":"Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: A cohort study","volume":"15","author":"Sacco","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jnci.2013.05.003_b0135","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4103\/0971-3026.82294","article-title":"Trans-arterial chemoembolization (TACE) in patients with unresectable Hepatocellular carcinoma: experience from a tertiary care centre in India","volume":"21","author":"Paul","year":"2011","journal-title":"Indian J Radiol Imaging"},{"key":"10.1016\/j.jnci.2013.05.003_b0140","first-page":"363","article-title":"Prevalence of hepatitis B virus in patients suffering from primary hepatocellular carcinoma","volume":"69","author":"Ahmed","year":"1986","journal-title":"J Egypt Med Assoc"},{"key":"10.1016\/j.jnci.2013.05.003_b0145","first-page":"1604","article-title":"Study on the role of schistosomiasis and hepatitis in the development of hepatocellular carcinoma","volume":"8","author":"El-Soudani","year":"1993","journal-title":"New Egypt J Med"},{"key":"10.1016\/j.jnci.2013.05.003_b0150","first-page":"1633","article-title":"Primary hepatocellular carcinoma and aflatoxicosis","volume":"8","author":"El-Sherif","year":"1993","journal-title":"New Egypt J Med"},{"key":"10.1016\/j.jnci.2013.05.003_b0155","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00004836-200108000-00006","article-title":"The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients","volume":"33","author":"Hassan","year":"2001","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jnci.2013.05.003_b0160","doi-asserted-by":"crossref","first-page":"714","DOI":"10.4269\/ajtmh.1999.60.714","article-title":"Hepatocellular carcinoma in Egyptians with and without a history of hepatitis B virus infection: association with hepatitis C virus (HCV) infection but not with HCV RNA level","volume":"60","author":"Yates","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jnci.2013.05.003_b0165","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijheh.2005.04.003","article-title":"Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt","volume":"208","author":"Ezzat","year":"2005","journal-title":"Int J Hyg Environ Health"},{"key":"10.1016\/j.jnci.2013.05.003_b0170","first-page":"1754","article-title":"Aflatoxins as a risk factor for hepatocellular carcinoma in Egypt, Mansoura Gastroenterology Center study","volume":"55","author":"Abdel-Wahab","year":"2008","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.jnci.2013.05.003_b0175","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11894-008-0010-2","article-title":"Early detection of liver cancer: diagnosis and management","volume":"10","author":"Volk","year":"2008","journal-title":"Curr Gastroenterol Rep"},{"issue":"4","key":"10.1016\/j.jnci.2013.05.003_b0180","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2214\/AJR.07.2755","article-title":"Transarterial chemoembolization in patients not eligible for liver transplantation: single-center results","volume":"190","author":"Herber","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jnci.2013.05.003_b0185","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1148\/radiol.10091473","article-title":"Chemoembolization for Hepatocellular Carcinoma:Comprehensive Imaging and Survival Analysis in a 172-Patient Cohort","volume":"255","author":"Lewandowski","year":"2010","journal-title":"Radiology"},{"key":"10.1016\/j.jnci.2013.05.003_b0190","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jnci.2013.05.003_b0195","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3748\/wjg.v16.i2.264","article-title":"Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China","volume":"16","author":"Shi","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jnci.2013.05.003_b0200","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jnci.2013.05.003_b0205","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00000421-200204000-00019","article-title":"Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus","volume":"25","author":"Ishikura","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jnci.2013.05.003_b0210","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1097\/01.COC.0000077936.97997.AB","article-title":"Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma","volume":"26","author":"Li","year":"2003","journal-title":"Am J Clin Oncol"},{"issue":"Suppl. 6","key":"10.1016\/j.jnci.2013.05.003_b0215","first-page":"743","article-title":"Radiation therapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma","volume":"59","author":"Tazawa","year":"2001","journal-title":"Nippon Rinsho"},{"key":"10.1016\/j.jnci.2013.05.003_b0220","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0360-3016(03)00434-6","article-title":"Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma","volume":"57","author":"Yamada","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jnci.2013.05.003_b0225","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep.510270617","article-title":"Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution","volume":"27","author":"Bruix","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jnci.2013.05.003_b0230","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199505113321903","article-title":"A comparison of Lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d\u2019Etude et de Traitement du Carcinome Hepatocellulaire","volume":"332","author":"Anonym","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jnci.2013.05.003_b0235","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jnci.2013.05.003_b0240","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0016-5085(88)90436-2","article-title":"Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma\u2014a randomized controlled trial","volume":"94","author":"Lin","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jnci.2013.05.003_b0245","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0168-8278(90)90110-D","article-title":"A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma","volume":"11","author":"Pelletier","year":"1990","journal-title":"J Hepatol"},{"key":"10.1016\/j.jnci.2013.05.003_b0250","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0168-8278(98)80187-6","article-title":"Treatment of unresectable hepatocellular carcinoma with Lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC","volume":"29","author":"Pelletier","year":"1998","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jnci.2013.05.003_b0255","first-page":"356","article-title":"Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins?","volume":"14","author":"Biolato","year":"2010","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jnci.2013.05.003_b0260","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00270-006-0062-3","article-title":"Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies","volume":"30","author":"Marelli","year":"2007","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jnci.2013.05.003_b0265","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1148\/radiol.2241011262","article-title":"Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials","volume":"224","author":"Camm\u00e0","year":"2002","journal-title":"Radiology"},{"key":"10.1016\/j.jnci.2013.05.003_b0270","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/HMER.S7132","article-title":"Update on new approaches in the management of hepatocellular carcinoma","volume":"2","author":"Cabibbo","year":"2010","journal-title":"Hepatic Med Evid Res"},{"key":"10.1016\/j.jnci.2013.05.003_b0275","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/cncr.11111","article-title":"Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma","volume":"97","author":"Ebied","year":"2003","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jnci.2013.05.003_b0280","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-2354.2008.00984.x","article-title":"A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma","volume":"18","author":"Mabed","year":"2009","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"10","key":"10.1016\/j.jnci.2013.05.003_b0285","first-page":"1171","article-title":"Retrospective studies and chart reviews","volume":"49","author":"Hess","year":"2004","journal-title":"Respir Care"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1110036213000605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1110036213000605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T18:20:39Z","timestamp":1563214839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1110036213000605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1110036213000605"],"URL":"https:\/\/doi.org\/10.1016\/j.jnci.2013.05.003","relation":{},"ISSN":["1110-0362"],"issn-type":[{"value":"1110-0362","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}